









市場
/
株式
/
nasdaq-vnda
/

Vanda Pharmaceuticals Inc

VNDA

6.840USD

-0.190-2.70%

終値 12/23, 16:00（ET）15分遅れの株価

404.21M時価総額

損失額直近12ヶ月PER



Vanda Pharmaceuticals Inc

6.840

-0.190-2.70%

概要企業名金融分析

概要

企業名

金融

分析

詳細情報 Vanda Pharmaceuticals Inc 企業名

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Vanda Pharmaceuticals Incの企業情報



企業コードVNDA

会社名Vanda Pharmaceuticals Inc

上場日Apr 12, 2006

最高経営責任者「CEO」Polymeropoulos (Mihael Hristos)

従業員数368

証券種類Ordinary Share

決算期末Apr 12

本社所在地Suite 300E

都市WASHINGTON

証券取引所NASDAQ OMX - NASDAQ BASIC

国United States of America

郵便番号20037

電話番号12027343400

ウェブサイトhttps://www.vandapharma.com/

企業コードVNDA

上場日Apr 12, 2006

最高経営責任者「CEO」Polymeropoulos (Mihael Hristos)

Vanda Pharmaceuticals Incの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

2.34M

+0.43%

Mr. Gunther Birznieks

Senior Vice President - Business Development

411.63K

+73.26%

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

329.46K

+118.08%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

+50.09%

Dr. Tage Honore, Ph.D.

Independent Director

123.47K

+92.19%

Ms. Anne Sempowski Ward

Independent Director

119.07K

+98.97%

Dr. Stephen Ray Mitchell, M.D.

Independent Director

97.08K

+116.43%

Mr. Timothy I. Williams

Senior Vice President, General Counsel, Secretary

Ms. Phaedra S. Chrousos

Independent Director

Mr. Joakim (Kim) Wijkstrom

Senior Vice President, Chief Marketing Officer

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

2.34M

+0.43%

Mr. Gunther Birznieks

Senior Vice President - Business Development

411.63K

+73.26%

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

329.46K

+118.08%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

+50.09%

Dr. Tage Honore, Ph.D.

Independent Director

123.47K

+92.19%

Ms. Anne Sempowski Ward

Independent Director

119.07K

+98.97%

収益内訳

通貨: USD更新時刻: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Fanapt

29.29M

55.70%

Hetlioz

16.19M

30.79%

PONVORY

7.10M

13.51%

会社から関連データがまだ開示されていません。

事業別

地域別

事業別USD

会社名

収益

比率

Fanapt

29.29M

55.70%

Hetlioz

16.19M

30.79%

PONVORY

7.10M

13.51%

株主

更新時刻: Sun, Nov 16

株主統計

種類

株主統計

比率

BlackRock Institutional Trust Company, N.A.

9.77%

The Vanguard Group, Inc.

6.02%

Renaissance Technologies LLC

5.88%

Millennium Management LLC

5.50%

Dimensional Fund Advisors, L.P.

4.34%

他の

68.49%

株主統計

比率

BlackRock Institutional Trust Company, N.A.

9.77%

The Vanguard Group, Inc.

6.02%

Renaissance Technologies LLC

5.88%

Millennium Management LLC

5.50%

Dimensional Fund Advisors, L.P.

4.34%

他の

68.49%

種類

株主統計

比率

Investment Advisor

28.53%

Investment Advisor/Hedge Fund

27.12%

Hedge Fund

20.23%

Individual Investor

7.19%

Research Firm

1.71%

Pension Fund

0.27%

Bank and Trust

0.20%

Sovereign Wealth Fund

0.19%

Family Office

0.09%

他の

14.45%

機関投資家保有株



更新時刻: Wed, Oct 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q3

373

46.45M

78.60%

-9.99M

2025Q2

417

50.75M

85.90%

-11.31M

2025Q1

426

48.51M

82.37%

-12.27M

2024Q4

444

46.48M

79.71%

-15.23M

2024Q3

446

47.42M

81.36%

-14.93M

2024Q2

445

46.99M

80.73%

-18.42M

2024Q1

434

53.50M

92.97%

-11.41M

2023Q4

445

55.38M

96.27%

-9.21M

2023Q3

446

56.79M

98.75%

-12.15M

2023Q2

434

60.42M

105.19%

-10.16M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

BlackRock Institutional Trust Company, N.A.

5.99M

10.13%

-31.47K

-0.52%

Jun 30, 2025

The Vanguard Group, Inc.

3.54M

5.99%

+46.84K

+1.34%

Jun 30, 2025

Renaissance Technologies LLC

3.45M

5.83%

-118.97K

-3.34%

Jun 30, 2025

Millennium Management LLC

3.12M

5.28%

+980.75K

+45.84%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

2.59M

4.38%

+46.08K

+1.81%

Jun 30, 2025

Tang Capital Management, LLC

2.35M

3.98%

Jun 30, 2025

Polymeropoulos (Mihael Hristos)

2.34M

3.95%

+10.00K

+0.43%

Aug 07, 2025

BlackRock Financial Management, Inc.

2.43M

4.12%

+286.64K

+13.35%

Jun 30, 2025

Acadian Asset Management LLC

1.73M

2.93%

-155.16K

-8.22%

Jun 30, 2025

Two Sigma Investments, LP

1.34M

2.26%

+925.23K

+225.21%

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

データなし

日付

種類

比率

データなし

よくある質問

Vanda Pharmaceuticals Incの上位5名の株主は誰ですか？



Vanda Pharmaceuticals Incの上位5名の株主は以下のとおりです。
BlackRock Institutional Trust Company, N.A.は5.99M株を保有しており、これは全体の10.13%に相当します。
The Vanguard Group, Inc.は3.54M株を保有しており、これは全体の5.99%に相当します。
Renaissance Technologies LLCは3.45M株を保有しており、これは全体の5.83%に相当します。
Millennium Management LLCは3.12M株を保有しており、これは全体の5.28%に相当します。
Dimensional Fund Advisors, L.P.は2.59M株を保有しており、これは全体の4.38%に相当します。